Early trial tests Two-Drug attack on Tough-to-Treat skin cancer
NCT ID NCT03501368
Summary
This early-stage study tested the safety and initial effectiveness of combining two cancer drugs, trametinib and ceritinib, in patients with advanced melanoma that could not be surgically removed. The trial involved 27 patients whose cancer had worsened despite previous standard treatments. The main goals were to find the safest dose of this combination and see if it could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.